Back to dashboard
CommercialCoverageMedium impact

Noninvasive Prenatal Screening for Fetal Aneuploidies, Microdeletions, Single-Gene Disorders, and Twin Zygosity Using Cell-Free Fetal DNA

Blue Cross & Blue Shield of Mississippi·MS · OB-GYN, Family Medicine, Internal Medicine·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBS Mississippi has updated their medical policy for noninvasive prenatal screening using cell-free fetal DNA, covering screening for fetal aneuploidies (like Down syndrome), microdeletions, single-gene disorders, and twin zygosity determination. This policy establishes coverage criteria and guidelines for various NIPT testing methods and technologies.

Action Required

Action needed
Billing team should review the updated BCBS Mississippi policy A.4.01.21 for noninvasive prenatal screening to understand current coverage criteria for cell-free fetal DNA testing. Ensure documentation supports medical necessity for NIPT orders and verify patient eligibility before scheduling tests. Contact BCBS Mississippi for specific billing codes and prior authorization requirements if not currently established in billing system.